211 related articles for article (PubMed ID: 16856450)
1. The first pediatric case of Staphylococcus aureus with heterogenous resistant to vancomycin endocarditis in Thailand.
Phongsamart W; Srifeungfung S; Tiensasitorn C; Vanprapar N; Chearskul S; Chokephaibulkit K
J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S264-8. PubMed ID: 16856450
[TBL] [Abstract][Full Text] [Related]
2. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
Appelbaum PC
Int J Antimicrob Agents; 2007 Nov; 30(5):398-408. PubMed ID: 17888634
[TBL] [Abstract][Full Text] [Related]
3. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.
Smith TL; Pearson ML; Wilcox KR; Cruz C; Lancaster MV; Robinson-Dunn B; Tenover FC; Zervos MJ; Band JD; White E; Jarvis WR
N Engl J Med; 1999 Feb; 340(7):493-501. PubMed ID: 10021469
[TBL] [Abstract][Full Text] [Related]
4. Methicillin-resistant Staphylococcus aureus infection with intermediate sensitivity to vancomycin: a case report and literature review.
Schairer J; Sankri-Tarbichi AG; Fairfax MR; Salimnia H; Guzman JA
J Intensive Care Med; 2008; 23(5):338-41. PubMed ID: 18701528
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
Leonard SN; Rybak MJ
J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
[TBL] [Abstract][Full Text] [Related]
6. Vancomycin-intermediate Staphylococcus aureus selected during vancomycin therapy of experimental endocarditis are not detected by culture-based diagnostic procedures and persist after treatment arrest.
Moreillon P; Bizzini A; Giddey M; Vouillamoz J; Entenza JM
J Antimicrob Chemother; 2012 Mar; 67(3):652-60. PubMed ID: 22167243
[TBL] [Abstract][Full Text] [Related]
7. Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin.
Mohan SS; McDermott BP; Cunha BA
Heart Lung; 2005; 34(1):69-71. PubMed ID: 15647736
[TBL] [Abstract][Full Text] [Related]
8. Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin.
Woods CW; Cheng AC; Fowler VG; Moorefield M; Frederick J; Sakoulas G; Meka VG; Tenover FC; Zwadyk P; Wilson KH
Clin Infect Dis; 2004 Apr; 38(8):1188-91. PubMed ID: 15095227
[TBL] [Abstract][Full Text] [Related]
9. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.
Charles PG; Ward PB; Johnson PD; Howden BP; Grayson ML
Clin Infect Dis; 2004 Feb; 38(3):448-51. PubMed ID: 14727222
[TBL] [Abstract][Full Text] [Related]
10. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
Sakoulas G; Moellering RC
Clin Infect Dis; 2008 Jun; 46 Suppl 5():S360-7. PubMed ID: 18462091
[TBL] [Abstract][Full Text] [Related]
11. Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1997 Aug; 46(33):765-6. PubMed ID: 9272582
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
Madrigal AG; Basuino L; Chambers HF
Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
[TBL] [Abstract][Full Text] [Related]
13. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
[TBL] [Abstract][Full Text] [Related]
14. Key considerations in the treatment of complicated staphylococcal infections.
Jones RN
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():3-9. PubMed ID: 18226084
[TBL] [Abstract][Full Text] [Related]
15. Treatment failure of methicillin-resistant Staphylococcus aureus endocarditis with linezolid.
Corne P; Marchandin H; Macia JC; Jonquet O
Scand J Infect Dis; 2005; 37(11-12):946-9. PubMed ID: 16308242
[TBL] [Abstract][Full Text] [Related]
16. First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand.
Trakulsomboon S; Danchaivijitr S; Rongrungruang Y; Dhiraputra C; Susaemgrat W; Ito T; Hiramatsu K
J Clin Microbiol; 2001 Feb; 39(2):591-5. PubMed ID: 11158112
[TBL] [Abstract][Full Text] [Related]
17. New agents for Staphylococcus aureus endocarditis.
Drees M; Boucher H
Curr Opin Infect Dis; 2006 Dec; 19(6):544-50. PubMed ID: 17075329
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus.
Fritsche TR; Rhomberg PR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):399-403. PubMed ID: 18178361
[TBL] [Abstract][Full Text] [Related]
19. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR
J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
[TBL] [Abstract][Full Text] [Related]
20. Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2000 Jan; 48(51-52):1165-7. PubMed ID: 11266244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
